An open-label, multi-center, expanded treatment protocol of oral panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and relapsed and refractory multiple myeloma

Trial Profile

An open-label, multi-center, expanded treatment protocol of oral panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and relapsed and refractory multiple myeloma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Panobinostat (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Expanded access
  • Sponsors Novartis
  • Most Recent Events

    • 21 Jul 2017 The trial has been completed in Sweden. (end date: 2017-05-15).
    • 06 Dec 2016 Preliminary results (n=49) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 02 Oct 2015 New Source identified and integrated (ClinicalTrials.gov.: NCT02568943 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top